Previous 10 | Next 10 |
The Medicines and Healthcare products Regulatory Agency ((MHRA)) has signed-off the Phase 1/2 trial in the U.K. evaluating Artelo Biosciences' ([[ARTL]] +5.7%) ART27.13, synthetic cannabinoid, in patients with cancer anorexia and weight loss. Enrollment expected to initiate before year e...
First patients on track for enrollment this year Targeting multi-billion market with no approved therapies for cancer-related anorexia LA JOLLA, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biop...
LA JOLLA, CA / ACCESSWIRE / November 11, 2020 / Artelo Biosciences, Inc. (NASDAQ:ARTL) , a clinical stage biopharmaceutical company developing therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced that it will be presenting at th...
Artelo Biosciences (ARTL): FY GAAP EPS of -$1.26 beats by $0.39.Cash of ~$2.14M.“This has been a pivotal year for Artelo, with notable clinical and operational progress alongside a successful financing to advance our programs toward meaningful milestones,” stated Grego...
Closed $7.6 Million Underwritten Public Offering Received Ethics Approval to Commence CAReS Study of ART27.13 in the UK Expanded Exclusive Worldwide License with Stony Brook University for Fatty Acid Binding Protein 5 (FABP5) i...
LA JOLLA, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL) , a clinical stage biopharmaceutical company focused on developing and commercializing treatments intended to modulate endogenous signaling pathways, including the endocannabinoid system,...
LA JOLLA, Calif., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL) , a clinical stage biopharmaceutical company focused on developing and commercializing treatments intended to modulate endogenous signaling pathways, including the endocannabinoid system, today...
Artelo Biosciences (ARTL) -17.6% on pricing 8.8M units at $0.75/unit, with each unit consisting of one share of common stock and a warrant to purchase one share of common stock at $0.75, for gross proceeds of ~$6.6M. Offering is expected to close on October 14, 2020.Underwriters' ov...
LA JOLLA, Calif., Oct. 09, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL) , a clinical stage biopharmaceutical company focused on developing and commercializing treatments intended to modulate endogenous signaling pathways, including the endocannabinoid system, today...
Gainers: Kiniksa Pharmaceuticals (KNSA) +18%, Humanigen (HGEN) +15%, Neuronetics (STIM) +16%, American Well (AMWL) +13%, Xtant Medical (XTNT) +5%.Losers: Corbus Pharmaceuticals (CRBP) -39%, Axovant Gene Therapies (AXGT)-20%, Iovance Bioth...
News, Short Squeeze, Breakout and More Instantly...
Artelo Biosciences Inc. Company Name:
ARTL Stock Symbol:
OTCMKTS Market:
Artelo Biosciences Inc. Website:
ART26.12 seeks to address a critical need in painful neuropathies, including chemotherapy-induced peripheral neuropathy for which there is no FDA-approved treatment Phase 1 trial results expected in the first half of 2025 SOLANA BEACH, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- A...
SOLANA BEACH, Calif., July 03, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological condit...
Inhibition of FABP5 Demonstrates Activity in Cancer, Psoriasis, and Anxiety Disorders Results from Several Research Studies Presented at the Annual ICRS Symposium SOLANA BEACH, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a c...